Tumor News and Research

RSS

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Tikcro Technologies Ltd. today announced that BioCancell reported results from a Phase I/IIa clinical trial to establish the safety, optimal dose and preliminary efficacy of BioCancell's lead drug-candidate, BC-819, as a treatment for pancreatic cancer.

3 Nov 2010

Mouse study indicates black raspberries can prevent colorectal cancer

Black raspberries are highly effective in preventing colorectal tumors in two mouse models of the disease, according to a University of Illinois at Chicago study. The findings are published in the November issue of Cancer Prevention Research.

3 Nov 2010

Jelly fish glow may help detect early stage cancer

Researcher Professor Norman Maitland of the Yorkshire Cancer Research Laboratory at York University, feels that this technology could be at least ten times better than CT scanners at detecting tumors. He explained, “Cancers deep within the body are difficult to spot at an early stage and early diagnosis is critical for the successful treatment of any form of cancer.

2 Nov 2010

Celldex third quarter net loss increases to $9.1 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.

2 Nov 2010

African Americans more likely to have uterine cancer recurrence

African Americans are more likely to have a recurrence of uterine cancer despite undergoing a total hysterectomy or a hysterectomy followed by radiation therapy, according to researchers at Henry Ford Hospital in Detroit.

2 Nov 2010

Researchers explain how adiponectin prevents stress-induced damage in heart

One of the many advantages of maintaining a normal body weight is having healthy fat, which in turn supports a healthy heart. Fat tissue is increasingly seen as more than just a storage depot - it's also an active secretory organ that normally produces high levels of a cardioprotective hormone called adiponectin. How adiponectin protects the hearts of healthy people has long been a mystery, and now a team led by Barbara Ranscht, Ph.D. and Pilar Ruiz-Lozano, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveals that the protein T-cadherin is the receptor that anchors adiponectin to heart cells.

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

PITs compounds induce cell death and limit tumor growth

A class of compounds that interferes with cell signaling pathways may provide a new approach to cancer treatment, according to a study published online this week in the Proceedings of the National Academy of Sciences (PNAS) Early Edition. The compounds, called PITs (non-phosphoinositide PIP3 inhibitors), limited tumor growth in mice by inducing cell death.

2 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

LCA releases 2010 National Report Card on Lung Cancer

Today, Lung Cancer Alliance (LCA) released its Annual National Report Card on Lung Cancer, an overall assessment of the nation's response to the continuing high mortality of lung cancer, the leading cancer killer.

2 Nov 2010

Long-term cell phone usage doubles risk of developing brain tumors

The highest-quality research data available suggests that long-term exposure to microwaves from cellular phones may lead to an increased risk of brain tumors, reports a paper in the November/December issue of Journal of Computer Assisted Tomography. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

2 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.

2 Nov 2010

IMRT safe and effective treatment for paranasal tumors: Study

Treating paranasal sinus cancer with three-dimensional radiation that conforms to the shape of the tumor-a technique that minimizes side effects such as severe dry mouth and vision problems-is safe and effective, research at Fox Chase Cancer Center shows. Aruna Turaka, M.D., radiation oncologist at Fox Chase, will present the results on November 2nd at the annual meeting of the American Society for Radiation Oncology.

1 Nov 2010

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced it will showcase Dynamic Edge™ Gating Technology, recently cleared by the U.S. Food and Drug Administration, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), now underway at the San Diego Convention Center.

1 Nov 2010

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

1 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.

1 Nov 2010

Sugar in excess leads to complications

In light of Diabetes Awareness Month, many people are showing increased interest in the topic of sugar and sugar alternatives. With the various forms of sugar available table sugar, high-fructose corn syrup, agave, and honey understanding the differences between sugars and their effects on the body is not all sweet.

1 Nov 2010

Oncimmune to present benefits of EarlyCDT-Lung cancer test at ACCP annual meeting

Oncimmune® LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in the risk assessment and early detection of lung cancer, today announced that two oral presentations and five poster presentations during this week's American College of Chest Physicians' (ACCP) annual meeting in Vancouver will collectively highlight the clinical and economic benefits of EarlyCDT-Lung.

1 Nov 2010

Tumor News and Research

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Mouse study indicates black raspberries can prevent colorectal cancer

Jelly fish glow may help detect early stage cancer

Celldex third quarter net loss increases to $9.1 million

African Americans more likely to have uterine cancer recurrence

Researchers explain how adiponectin prevents stress-induced damage in heart

New targeted therapy shows positive results in patients with lung cancer

PITs compounds induce cell death and limit tumor growth

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

LCA releases 2010 National Report Card on Lung Cancer

Long-term cell phone usage doubles risk of developing brain tumors

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

IMRT safe and effective treatment for paranasal tumors: Study

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

Sugar in excess leads to complications

Oncimmune to present benefits of EarlyCDT-Lung cancer test at ACCP annual meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News